[CAS NO. 59803-98-4] Brimonidine

Name: Brimonidine
Brand: Arctom Scientific
SKU: AS426703

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [59803-98-4]

Distributor

Catalog

AS426703

Brand

Arctom Scientific

CAS

59803-98-4

DESCRIPTION [59803-98-4]

Overview

MDL	MFCD00153878
Molecular Weight	292.13
Molecular Formula	C11H10BrN5
SMILES	BrC1=C2N=CC=NC2=CC=C1NC3=NCCN3

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

Brimonidine (UK 14304) is a full α2-adrenergic receptor (α2-AR) agonist.

IC50 & Target

α2-adrenergic Receptor.

In Vitro

[3H]Brimonidine (UK 14304) is a full agonist at alpha 2-adrenergic receptors. [3H]Brimonidine (UK 14304) labels at least 2 specific binding sites in human brain that both have the characteristics of an alpha 2-adrenergic binding site. GTP decreases agonist binding at both of these sites, but with different potencies at each site [1-3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05360784	Bausch & Lomb Incorporated	Ocular Redness	May 13, 2022	Phase 3
NCT00972374	Allergan	Rhegmatogenous Macula-off Retinal Detachment	November 2009	Phase 2
NCT00435058	University of Sao Paulo	Glaucoma	September 2005	Not Applicable
NCT03192826	University Hospital of Patras	Posterior Capsule Opacification\|Ocular Hypertension	June 20, 2016	Phase 4
NCT01250236	Augenarztpraxis Breisach	Impact of Brimonidine on the Cornea	December 2010
NCT03497442	University of California, San Francisco	Flushing\|Alcohol-Related Disorders\|Aldehyde Dehydrogenase Deficiency	July 12, 2018	Early Phase 1
NCT00352807	Indiana University School of Medicine\|Allergan\|Indiana University	Cataract	February 2005	Not Applicable
NCT01201551	University Hospital, Basel, Switzerland	Primary Vascular Dysregulation	June 2011	Not Applicable
NCT01151904	Allergan	Glaucoma, Angle-Closure	November 2009	Phase 4
NCT02764411	The Hospital for Sick Children\|Galderma R&D	Capillary Malformations	June 2016	Phase 3
NCT03959176	Wake Forest University Health Sciences	Intraocular Pressure	July 20, 2019	Phase 4
NCT02568111	Biogen	Relapsing-Remitting Multiple Sclerosis (RRMS)	February 2016	Phase 4
NCT03591874	Ocugen	Graft Versus Host Disease\|Ocular Surface Disease\|oGVHD\|Ocular Graft vs Host Disease\|Brimonidine Tartrate\|Lubricant Eye Drops\|Ophthalmic Solutions\|Graft vs Host Disease	December 23, 2018	Phase 3
NCT00822081	Bp Consulting, Inc\|Allergan	Open-Angle Glaucoma\|Ocular Hypertension	January 2005	Phase 4
NCT01297517	Alcon Research	Open-Angle Glaucoma\|Ocular Hypertension	February 2011	Phase 3
NCT00347035	Federal University of São Paulo	Glaucoma		Phase 4
NCT04633954	Uptown Eye Specialists	Subconjunctival Hemorrhage\|Cataract Surgery	June 6, 2019	Not Applicable
NCT03760185	Denver Health and Hospital Authority	Intraoperative Floppy Iris Syndrome	January 4, 2019	Phase 2
NCT05474716	Fayoum University	Glaucoma, Primary Open Angle\|Ocular Blood Flow\|Optical Coherence Tomography Angiography	May 1, 2020	Phase 4
NCT02856919	Galderma Brasil Ltda.\|Eurotrials Brasil Consultores Cientificos Ltda	Chronic Persistent Vascular Facial Erythema	June 13, 2016	Phase 4
NCT02339584	Alcon Research	Open-Angle Glaucoma\|Ocular Hypertension	April 14, 2015	Phase 3
NCT01959230	Bausch & Lomb Incorporated\|ORA, Inc.	Hyperemia	November 7, 2013	Phase 3
NCT01310777	Alcon Research	Open-Angle Glaucoma\|Ocular Hypertension	May 2011	Phase 3
NCT02385240	Padagis LLC	Rosacea	March 2015	Phase 3
NCT00712777	Medical University of Vienna	Ocular Physiology\|Intraocular Pressure	March 2008	Not Applicable
NCT00457795	Allergan	Open-angle Glaucoma\|Ocular Hypertension	December 2006	Phase 4
NCT02039765	Bausch & Lomb Incorporated\|ORA, Inc.	Hyperemia	February 2014	Phase 1
NCT00706927	Medical University of Vienna	Retina\|Ocular Physiology	January 2006	Not Applicable
NCT00402493	Philadelphia Eye Associates\|Pfizer	Glaucoma\|Ocular Hypertension	December 2006	Not Applicable
NCT03418727	Ocugen	Dry Eye	September 6, 2017	Phase 2
NCT04683159	Uptown Eye Specialists	Pterygium\|Subconjunctival Hemorrhage	February 2021	Not Applicable
NCT02761174	Merete Haedersdal\|Skinperium, Christine Dierickx\|Ellipse A+S Agern Allé 11, 2970 Hørsholm\|Bispebjerg Hospital	Telangiectasias	March 13, 2016	Phase 4
NCT02616250	Galderma R&D	Rosacea	December 2015	Phase 4
NCT05270863	Visus Therapeutics	Presbyopia	March 30, 2022	Phase 3
NCT00466479	University of Parma	Glaucoma	August 1999	Phase 4
NCT00800540	Alcon Research	Glaucoma	February 2009	Phase 4
NCT02003534	Allergan	Glaucoma, Open-Angle\|Ocular Hypertension	July 2010	Phase 4
NCT02147691	Derm Research, PLLC\|Bayer Healthcare Pharmaceuticals, Inc.+Bayer Schering Pharma	Acne Rosacea	May 2014	Phase 4
NCT01885000	Galderma R&D	Rosacea\|Erythema	July 1, 2013	Phase 3
NCT03966560	Afyon Kocatepe University Hospital	Glaucoma, Open-Angle	January 2014	Phase 4
NCT03173365	Heinrich-Heine University, Duesseldorf	Hand-foot Syndrome	July 10, 2017	Phase 2
NCT00312416	Medical University of Vienna	Ocular Physiology\|Regional Blood Flow	February 2004	Phase 4
NCT01144494	University of Nebraska	Intraocular Pressure	June 2010	Not Applicable
NCT01426867	Alcon Research	Open-Angle Glaucoma\|Ocular Hypertension	September 2011	Phase 2
NCT00822055	Allergan	Open-Angle Glaucoma\|Ocular Hypertension	May 2005	Phase 4
NCT01959243	Bausch & Lomb Incorporated\|ORA, Inc.	Hyperemia	February 22, 2014	Phase 3
NCT01726075	BCN Peptides	Diabetic Retinopathy	February 2013	Phase 2\|Phase 3
NCT05591755	Bausch & Lomb Incorporated	Seasonal Allergic Conjunctivitis	December 22, 2022	Phase 3
NCT00735449	Allergan	Glaucoma\|Ocular Hypertension	July 2008	Phase 4
NCT03785340	Ocugen	Dry Eye	December 3, 2018	Phase 3
NCT00864838	University of Sao Paulo\|Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP	Age Related Macular Degeneration\|Diabetic Retinopathy	June 2008	Phase 2
NCT03508869	Skin Laser & Surgery Specialists\|Galderma R&D	Erythema and Flushing Associated With Rosacea	September 27, 2016	Not Applicable
NCT02289352	Actavis Inc.\|Watson Laboratories, Inc.	Rosacea	July 2014	Phase 3
NCT02818816	University Health Network, Toronto	Prostate Cancer	February 29, 2016	Phase 4
NCT01297920	Alcon Research	Open-Angle Glaucoma\|Ocular Hypertension	March 2011	Phase 3
NCT03220490	Sheba Medical Center	Glaucoma\|Glaucoma; Drugs	November 1, 2017	Not Applicable
NCT04647461	CHA University\|Hanlim Pharm. Co., Ltd.	Glaucoma\|Ocular Hypertensive	March 20, 2019	Phase 4
NCT00567411	Walter Reed Army Medical Center	Glaucoma\|Ocular Hypertension	August 2006	Not Applicable
NCT00824824	Massachusetts Eye and Ear Infirmary	Glaucoma	January 2009	Not Applicable
NCT01229462	Allergan	Glaucoma\|Ocular Hypertension	October 2010	Not Applicable
NCT02087085	Allergan	Geographic Atrophy\|Macular Degeneration	May 9, 2014	Phase 2
NCT00658619	Allergan	Macular Degeneration	May 1, 2008	Phase 2
NCT00811564	Allergan	Glaucoma\|Ocular Hypertension	December 2008	Phase 4
NCT01275105	Eye Therapies, LLC\|ORA, Inc.	Allergic Conjunctivitis	January 2011	Phase 2
NCT01525173	Allergan	Glaucoma\|Ocular Hypertension	January 2012	Phase 4
NCT01687426	Eye Therapies, LLC	Glaucoma and Ocular Hypertension	September 2012	Phase 1
NCT03193333	Laboratorios Sophia S.A de C.V.	Primary Open-angle Glaucoma	November 6, 2017	Phase 3
NCT01004900	Singapore Eye Research Institute	Glaucoma	June 2009	Phase 3
NCT00661479	Allergan	Retinitis Pigmentosa	July 2008	Phase 1\|Phase 2
NCT01217606	Allergan	Glaucoma, Open-Angle\|Ocular Hypertension	January 2011	Phase 3
NCT05579730	Bausch & Lomb Incorporated	Allergic Conjunctivitis	December 12, 2022	Phase 3
NCT01309204	Alcon Research	Open-Angle Glaucoma\|Ocular Hypertension	May 2011	Phase 3
NCT02975557	Sandeep Jain, MD\|Ocugen\|University of Illinois at Chicago	Dry Eye\|Ocular Graft vs Host Disease\|Meibomian Gland Dysfunction	May 2016	Phase 1\|Phase 2
NCT03782701	University of Miami	Eyelid Droop	June 18, 2019	Phase 4
NCT04007276	Tulane University	Glaucoma\|Glaucoma, Open-Angle\|Glaucoma; Drugs\|Droopy Eyelid\|Ptosis\|Glaucoma, Primary Open Angle	November 10, 2025	Phase 4
NCT03450629	Sun Pharma Advanced Research Company Limited	Open Angle Glaucoma\|Ocular Hypertension	September 13, 2018	Phase 3
NCT01170884	Allergan	Glaucoma\|Ocular Hypertension	December 2009	Phase 4
NCT05480098	University of Louisville	Dermatochalasis of Eyelid\|Ptosis, Eyelid\|Ectropion\|Entropion	May 26, 2022	Phase 4
NCT02140450	Mashhad University of Medical Sciences	Intraocular Pressure Change in Intravitreal Injection	February 2012	Not Applicable
NCT01863953	Allergan	Glaucoma\|Ocular Hypertension	June 2013	Phase 2
NCT00168363	Allergan	Glaucoma\|Ocular Hypertension	January 2005	Phase 3
NCT00811850	Allergan	Glaucoma	December 2008	Phase 4
NCT00651612	Allergan	Glaucoma\|Ocular Hypertension	November 2005	Phase 3
NCT01241240	Allergan	Glaucoma, Open-Angle\|Ocular Hypertension	March 2011	Phase 3
NCT00693485	Allergan	Glaucoma, Open-Angle	September 2008	Phase 2
NCT00061529	Alcon Research	Open-Angle Glaucoma\|Ocular Hypertension	January 2003	Phase 3
NCT01229410	Allergan	Vitrectomy	December 2010	Phase 1
NCT03048058	Wake Forest University Health Sciences	Rosacea	May 5, 2016	Phase 4
NCT05001243	Optall Vision	Presbyopia	August 10, 2021	Phase 1
NCT01105065	Massachusetts Eye and Ear Infirmary	Glaucoma	March 2010	Not Applicable
NCT00697541	Galderma R&D	Erythematous Rosacea	May 2008	Phase 2
NCT00348400	Innovative Medical	Glaucoma		Phase 4
NCT01987752	Allergan	Glaucoma, Open-Angle\|Ocular Hypertension	January 2009
NCT03513172	University of Toronto\|Dr. Efrem Mandelcorn	Post-Injection Intraocular Pressure Spikes	December 15, 2016	Not Applicable
NCT02863705	Allergan	Glaucoma, Open-Angle\|Normal Tension Glaucoma	July 5, 2016	Phase 4
NCT00675207	Northwestern Ophthalmic Institute S.C.\|Research to Prevent Blindness	Primary Open Angle Glaucoma\|Ocular Hypertension	January 2006	Phase 4
NCT02249065	Galderma R&D	Rosacea	September 2014	Phase 4
NCT01345448	Nanduri, Padma, M.D., FACS	Glaucoma	April 2011	Phase 2
NCT00804921	University of Sao Paulo	Macular Edema\|Diabetic Retinopathy\|Macular Degeneration		Phase 2
NCT02602470	LEO Pharma\|Bayer	Rosacea	January 8, 2015
NCT00275756	Medical University of Vienna	Glaucoma	September 2008	Not Applicable
NCT00413751	Walter Reed Army Medical Center	Healthy
NCT00800423	Rabin Medical Center	Corneal Edema\|Visual Acuity	January 2009	Phase 3
NCT03323164	Wills Eye\|Optovue	Glaucoma; Drugs\|Normal Tension Glaucoma\|Primary Open-angle Glaucoma	July 10, 2017	Phase 4
NCT00652483	Allergan	Glaucoma\|Ocular Hypertension	May 2003	Phase 3
NCT00961649	Alcon Research	Open-Angle Glaucoma\|Ocular Hypertension	October 2009	Phase 2
NCT00440141	Allergan	Glaucoma\|Ocular Hypertension	July 2006	Phase 4
NCT01675609	Eye Therapies, LLC	Ocular Redness	August 2012	Phase 2
NCT00652106	Allergan	Glaucoma\|Ocular Hypertension	June 2003	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 171.16 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4231 mL	17.1157 mL	34.2313 mL
5 mM	0.6846 mL	3.4231 mL	6.8463 mL
10 mM	0.3423 mL	1.7116 mL	3.4231 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (8.56 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.56 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: 2.5 mg/mL (8.56 mM); Clear solution; Need warming

* All of the co-solvents are available by MCE.

References

Synonyms

6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine

UK 14304

5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline

UK 14304-18

Brimonidine

Bromoxidine

AGN 190342

Lyuksfen